Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen cash
Cash and short-term investments held at the end of each period.
Neogen's cash was $172.00M at Aug 31, 2026. For fiscal 2026 it was $185.50M, up 43.8% from the year before. Over ten years it grew 5.6% a year on average. The highest annual figure on record is $381.09M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $185.50M | +43.8% |
| FY2025 | May 31, 2025 | $129.00M | -24.5% |
| FY2024 | May 31, 2024 | $170.93M | -30.4% |
| FY2023 | May 31, 2023 | $245.53M | -35.6% |
| FY2022 | May 31, 2022 | $381.05M | -0.0% |
| FY2021 | May 31, 2021 | $381.09M | +10.9% |
| FY2020 | May 31, 2020 | $343.67M | +28.5% |
| FY2019 | May 31, 2019 | $267.52M | +26.9% |
| FY2018 | May 31, 2018 | $210.81M | +46.8% |
| FY2017 | May 31, 2017 | $143.64M | +33.2% |
| FY2016 | May 31, 2016 | $107.80M | -5.6% |
| FY2015 | May 31, 2015 | $114.16M | +49.2% |
| FY2014 | May 31, 2014 | $76.50M | -10.4% |
| FY2013 | May 31, 2013 | $85.37M | +24.4% |
| FY2012 | May 31, 2012 | $68.65M | +22.4% |
| FY2011 | May 31, 2011 | $56.08M | +145.9% |
| FY2010 | May 31, 2010 | $22.81M | +64.8% |
| FY2009 | May 31, 2009 | $13.84M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $172.00M | +23.9% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $185.50M | +43.8% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $159.90M | +25.2% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $145.34M | +3.6% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $138.80M | +15.2% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $129.00M | -24.5% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $127.70M | -24.2% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $140.23M | -24.6% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $120.48M | -49.6% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $170.93M | -30.4% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $168.45M | -8.1% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $185.94M | -32.7% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $239.26M | -31.2% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $245.53M | -35.6% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $183.21M | -51.6% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $276.34M | -29.0% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $347.71M | -13.3% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $381.05M | -0.0% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $378.44M | +7.1% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $389.25M | -0.4% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $400.88M | +9.1% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $381.09M | +10.9% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $353.35M | +7.8% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $390.77M | +24.6% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $367.49M | +26.3% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $343.67M | +28.5% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $327.92M | +32.9% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $313.61M | +30.1% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $291.02M | +28.5% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $267.52M | +26.9% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $246.68M | +28.4% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $240.97M | +37.0% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $226.41M | +41.5% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $210.81M | +46.8% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $192.16M | +54.2% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $175.84M | +23.7% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $159.99M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $143.64M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $124.58M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $142.11M | – |
See a number that looks wrong?